Sangamo Therapeutics, INC Form 4 insider transactions

Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, reported a mandatory tax withholding transaction involving 1,630 shares.

Principal Accounting Officer Nikunj Jain reported the disposition of 1,919 shares to satisfy mandatory tax withholding obligations.

SVP-Chief Development Officer Nathalie Dubois-Stringfellow disposed of 4,036 shares to satisfy mandatory tax obligations.

Scott B. Willoughby, SVP and Chief Legal Officer of Sangamo Therapeutics, reported a mandatory tax withholding transaction of 4,036 shares.

CEO Sandy Macrae disposed of 12,613 shares of Sangamo Therapeutics to satisfy mandatory tax withholding obligations related to RSU vesting.

Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, Inc., reported a sale of common stock on April 22, 2026.

Nathalie Dubois-Stringfellow, SVP-Chief Development Officer at Sangamo Therapeutics, reported a sale of common stock on April 21, 2026.

Nathalie Dubois-Stringfellow, SVP-Chief Development Officer at Sangamo Therapeutics, received a stock option grant for 800,000 shares.

Nikunj Jain, Principal Accounting Officer at Sangamo Therapeutics, received a stock option grant for 225,000 shares.

Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, was granted stock options for 225,000 shares.

Sangamo Therapeutics, Inc. reports that President, CEO, and Director Sandy Macrae was granted stock options for 2.5 million shares.

SVP-Chief Development Officer Nathalie Dubois-Stringfellow reported the disposition of shares for mandatory tax withholding related to restricted stock unit vesting.

Sangamo Therapeutics CEO Sandy Macrae disposed of common stock solely for mandatory tax withholding related to restricted stock unit vesting.

Sangamo Therapeutics' SVP, Chief Legal Officer, Scott B. Willoughby, reported routine dispositions of common stock for mandatory tax withholding related to RSU vestings.

Sangamo Therapeutics' Principal Accounting Officer, Nikunj Jain, reported the disposition of shares for mandatory tax withholding following RSU vesting.

Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics, reported routine share dispositions for tax withholding related to restricted stock unit vesting.

Sangamo Therapeutics' Principal Accounting Officer, Nikunj Jain, reported a disposition of shares for mandatory tax withholding related to restricted stock unit vesting.

Sangamo Therapeutics' Principal Financial Officer, Prathyusha Duraibabu, reported a disposition of 36,676 shares of common stock for mandatory tax withholding purposes.

Sangamo Therapeutics' SVP, Chief Legal Officer, Scott B. Willoughby, disposed of 36,676 common shares for mandatory tax withholding related to vested restricted stock units.

Sangamo Therapeutics CEO Sandy Macrae reported the surrender of 102,950 shares for mandatory tax withholding related to vested restricted stock units.

Sangamo Therapeutics' Head of Research & Technology, Gregory D. Davis, reported a disposition of shares for mandatory tax withholding related to restricted stock unit vesting.

A Sangamo Therapeutics executive disposed of 36,676 shares of common stock for mandatory tax withholding purposes following an RSU vesting event.

Sangamo Therapeutics' Principal Accounting Officer, Nikunj Jain, reported a disposition of 578 shares for mandatory tax withholding related to restricted stock unit vesting.

Scott B. Willoughby, SVP, Chief Legal Officer, and Secretary of Sangamo Therapeutics, Inc., disposed of 2,035 shares of common stock for mandatory tax withholding purposes following an RSU vesting.

Sangamo Therapeutics CEO Sandy Macrae disposed of 7,488 shares of common stock to cover tax liabilities related to vested restricted stock units.

Sangamo Therapeutics' Principal Financial Officer, Prathyusha Duraibabu, disposed of 2,544 common shares for mandatory tax withholding following an RSU vesting event.

SVP-Chief Development Officer Nathalie Dubois-Stringfellow reported a routine disposition of 2,544 Sangamo Therapeutics shares for tax withholding following an RSU vesting event.

Sangamo Therapeutics' Head of Research & Technology, Gregory D. Davis, disposed of 723 shares for mandatory tax withholding related to RSU vesting.

SANGAMO THERAPEUTICS' SVP-Chief Development Officer, Nathalie Dubois-Stringfellow, disposed of 43,741 shares of common stock for mandatory tax withholding related to RSU vesting.

Sangamo Therapeutics' SVP and Chief Legal Officer, Scott B. Willoughby, disposed of 44,122 shares of common stock for mandatory tax withholding related to RSU vesting.